Education
About Us
Working with TipRanks
Follow Us
JW (Cayman) Therapeutics Co. Ltd. (DE:JNY)
FRANKFURT:JNY
Total Valuation
JW (Cayman) Therapeutics Co. Ltd. has a market cap or net worth of HK$81.61M. The enterprise value is ―.
Market CapHK$81.61M
Enterprise Value―
Share Statistics
JW (Cayman) Therapeutics Co. Ltd. has 416,196,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding416,196,440
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
JW (Cayman) Therapeutics Co. Ltd.’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -28.86%.
Return on Equity (ROE)-0.51
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-28.86%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee563.05K
Profits Per Employee-2.10M
Employee Count281
Asset Turnover0.09
Inventory Turnover2.59
Valuation Ratios
The current PE Ratio of JW (Cayman) Therapeutics Co. Ltd. is -0.84. JW (Cayman) Therapeutics Co. Ltd.’s PEG ratio is -0.18.
PE Ratio-0.84
PS Ratio0.00
PB Ratio0.53
Price to Fair Value0.43
Price to FCF-3.16
Price to Operating Cash Flow-3.27
PEG Ratio-0.18
Income Statement
In the last 12 months, JW (Cayman) Therapeutics Co. Ltd. had revenue of 158.22M and earned -590.62M in profits. Earnings per share was -1.43.
Revenue158.22M
Gross Profit77.32M
Operating Income-466.15M
Pretax Income-590.62M
Net Income-590.62M
EBITDA-381.58M
Earnings Per Share (EPS)-1.43
Cash Flow
In the last 12 months, operating cash flow was -188.20M and capital expenditures -2.87M, giving a free cash flow of -191.07M billion.
Operating Cash Flow-188.20M
Free Cash Flow-191.07M
Free Cash Flow per Share-0.46
Dividends & Yields
JW (Cayman) Therapeutics Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.67
52-Week Price Change-23.14%
50-Day Moving Average0.19
200-Day Moving Average0.18
Relative Strength Index (RSI)55.76
Average Volume (3m)0.00
Important Dates
JW (Cayman) Therapeutics Co. Ltd. upcoming earnings date is Mar 25, 2026, TBA Not Confirmed.
Last Earnings DateSep 2, 2025
Next Earnings DateMar 25, 2026
Ex-Dividend Date―
Financial Position
JW (Cayman) Therapeutics Co. Ltd. as a current ratio of 1.74, with Debt / Equity ratio of 36.13%
Current Ratio1.74
Quick Ratio1.67
Debt to Market Cap0.77
Net Debt to EBITDA0.88
Interest Coverage Ratio0.00
Taxes
In the past 12 months, JW (Cayman) Therapeutics Co. Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
JW (Cayman) Therapeutics Co. Ltd. EV to EBITDA ratio is -0.43, with an EV/FCF ratio of 0.00.
EV to Sales1.03
EV to EBITDA-0.43
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
JW (Cayman) Therapeutics Co. Ltd. has HK$757.38M in cash and marketable securities with ¥422.40M in debt, giving a net cash position of -HK$334.97M billion.
Cash & Marketable SecuritiesHK$757.38M
Total Debt¥422.40M
Net Cash-HK$334.97M
Net Cash Per Share-HK$0.80
Tangible Book Value Per ShareHK$1.42
Margins
Gross margin is 48.87%, with operating margin of -290.28%, and net profit margin of -373.30%.
Gross Margin48.87%
Operating Margin-290.28%
Pretax Margin-373.30%
Net Profit Margin-373.30%
EBITDA Margin-241.17%
EBIT Margin-290.13%
Analyst Forecast
The average price target for JW (Cayman) Therapeutics Co. Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―